NAPRT and ovarian cancer: To rapidly screen the 50 selected compounds for their ability to inhibit NAPRT, we used their capacity to sensitize the NAPRT-proficient ovarian cancer cell line, OVCAR-5, to FK866 as a reading frame (since this cell line is normally resistant to the NAMPT inhibitor but becomes sensitized to it through either NAPRT silencing or inhibition).